Publications
137 results found
Culpitt SV, Rogers DF, 2000, Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease., Expert Opin Pharmacother, Vol: 1, Pages: 1007-1020, ISSN: 1465-6566
Chronic obstructive pulmonary disease (COPD) is a severe chronic respiratory condition characterised by progressive, irreversible airflow limitation. It is common, affecting more than 16 million people in the United States and is the fourth highest cause of death. The worldwide incidence of COPD is increasing and, in parallel, the economic and social burden the disease incurs. The treatment of COPD is symptomatic, with no drugs currently available to halt the relentless progression of airflow obstruction. However, with a better understanding of the pathological features of the airway inflammation and alveolar destruction that characterises COPD, new therapeutic strategies are being developed. This article provides a critical evaluation of current pharmacotherapy in COPD, essentially bronchodilators (anticholinergics, beta 2-adrenoceptor agonists and theophylline) and corticosteroids, and an overview of international recommendations for their use.
Nightingale JA, Rogers DF, Chung KF, et al., 2000, No effect of inhaled budesonide on the response to inhaled ozone in normal subjects, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 161, Pages: 479-486, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 52
Nightingale JA, Rogers DF, Chung KF, et al., 2000, No effect of inhaled budesonide on the response to inhaled ozone in normal subjects, American Journal of Respiratory and Critical Care Medicine, Vol: 161, Pages: 479-486, ISSN: 1073-449X
Inhalation of ozone in normal subjects causes a neutrophilic inflammatory response in the airways. Pretreatment with inhaled corticosteroids reduces the inflammatory response to inhaled ozone in dogs. We undertook a double-blind, randomized, placebo-controlled, crossover study to investigate the effects of 2 wk of treatment with inhaled budesonide 800 μg twice daily or placebo prior to ozone exposure in humans. Fifteen (six male; mean age, 31.1 ± 2.1 yr) healthy nonsmokers were exposed to 400 parts per billion (ppb) ozone for 2 h with intermittent exercise. Spirometry, exhaled carbon monoxide (CO) and nitric oxide (NO) levels, measurement of methacholine reactivity, and collection of exhaled air condensate and induced sputum samples were performed at baseline, preexposure, and at intervals up to 24 h postexposure. Ozone exposure led to significant decreases in spirometry and increased methacholine reactivity and sputum neutrophils and myeloperoxidase (MPO). There were no changes in exhaled NO and CO levels, or exhaled breath nitrite after ozone exposure. There were no differences in any of the parameters after treatment with budesonide compared with placebo, and no differences in the response to ozone between treatment groups. We conclude that a high dose of inhaled corticosteroid does not protect against the effects of ozone exposure in normal subjects.
Nightingale JA, Rogers DF, Barnes PJ, 1999, Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects, THORAX, Vol: 54, Pages: 1061-1069, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 85
Khawaja AM, Liu YC, Rogers DF, 1999, Effect of non-peptide tachykinin NK<sub>1</sub> receptor antagonists on non-adrenergic, non-cholinergic neurogenic mucus secretion in ferret trachea, EUROPEAN JOURNAL OF PHARMACOLOGY, Vol: 384, Pages: 173-181, ISSN: 0014-2999
- Author Web Link
- Cite
- Citations: 18
Liu YC, Khawaja AM, Rogers DF, 1999, Effect of vasoactive intestinal peptide (VIP)-related peptides on cholinergic neurogenic and direct mucus secretion in ferret trachea <i>in vitro</i>, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 128, Pages: 1353-1359, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 17
Rogers DF, Barnes PJ, 1999, COPD: new developments and therapeutic opportunities., Trends Pharmacol Sci, Vol: 20, Pages: 352-354, ISSN: 0165-6147
Nightingale JA, Rogers DF, Barnes PJ, 1999, Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 159, Pages: 1786-1790, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 37
Rush AK, Liu YC, Price S, et al., 1999, Effect of lipopolysaccharide on mucin gene expression in rat lung <i>in vivo</i>, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 159, Pages: A474-A474, ISSN: 1073-449X
Nightingale JA, Cullinan P, Ashmore M, et al., 1999, Inflammatory effects of inhaled diesel exhaust particulates in normal subjects., AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 159, Pages: A317-A317, ISSN: 1073-449X
Witherden IR, Liu YC, Goldstraw P, et al., 1999, Mucin gene expression and protein production by primary human alveolar type II cells compared with lung tumour cell lines <i>in vitro</i>, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 159, Pages: A174-A174, ISSN: 1073-449X
Lei YH, Rogers DF, 1999, Effects and interactions of opioids on plasma exudation induced by cigarette smoke in guinea pig bronchi, AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, Vol: 276, Pages: L391-L397, ISSN: 1040-0605
- Author Web Link
- Cite
- Citations: 6
Liu YC, Patel HJ, Khawaja AM, et al., 1999, Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea:: activation of BK<sub>Ca</sub> channels and inhibition of neurotransmitter release, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 126, Pages: 147-158, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 15
Khawaja AM, Liu YC, Rogers DF, 1999, Effect of fenspiride, a non-steroidal antiinflammatory agent, on neurogenic mucus secretion in ferret trachea in vitro, PULMONARY PHARMACOLOGY & THERAPEUTICS, Vol: 12, Pages: 363-368, ISSN: 1094-5539
- Author Web Link
- Cite
- Citations: 8
Nightingale JA, Rogers DF, Barnes PJ, 1998, Effect of repeated sputum induction on cell counts in normal volunteers, Pneumologie, Vol: 52, Pages: 400-401, ISSN: 0934-8387
- Cite
- Citations: 1
Rogers DF, Giembycz MA, 1998, Conquering airway inflammation in the 21st century, DRUG DISCOVERY TODAY, Vol: 3, Pages: 532-535, ISSN: 1359-6446
- Author Web Link
- Cite
- Citations: 4
Nightingale JA, Rogers DF, Hart LA, et al., 1998, Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects, THORAX, Vol: 53, Pages: 563-571, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 88
Liu YC, Khawaja AM, Rogers DF, 1998, Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs <i>in vitro</i>, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 124, Pages: 563-571, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 41
Rogers DF, Giembycz MA, 1998, Asthma therapy for the 21st century, TRENDS IN PHARMACOLOGICAL SCIENCES, Vol: 19, Pages: 160-164, ISSN: 0165-6147
- Author Web Link
- Cite
- Citations: 24
Ramnarine SI, Liu YC, Rogers DF, 1998, Neuroregulation of mucus secretion by opioid receptors and K<sub>ATP</sub> and BK<sub>Ca</sub> channels in ferret trachea <i>in vitro</i>, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 123, Pages: 1631-1638, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 23
Rogers DF, Laurent GJ, 1998, New ideas on the pathophysiology and treatment of lung disease, THORAX, Vol: 53, Pages: 200-203, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 14
Nightingale JA, Rogers DF, Barnes PJ, 1998, Effect of repeated sputum induction on cell counts in normal volunteers, THORAX, Vol: 53, Pages: 87-90, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 78
Nightingale JA, Hart LA, Kharitonov SA, et al., 1997, Effects of inhaled lipopolysacharide on neutrophil numbers in induced sputum in normal and asthmatic subjects, Thorax, Vol: 52, ISSN: 0040-6376
Previous studies have shown that inhalation of lipopolysaccharide (LPS) causes an inflammatory response in the lungs. In a double-blind, randomised, placebo-controlled crossover trial we have used inhaled LPS (E. Coli) to explore whether LPS-induced inflammation alters lung function or cell counts in induced sputum. 11 healthy subjects (age 25.4±1.6 yr) and 7 asthmatic volunteers (age 29±2 yr) inhaled LPS (60μg) or placebo (0.9% saline). All subjects were male and non-smokers. All subjects underwent sputum induction by inhalation of 3.5% saline via a DeVilbiss nebuliser prior to the test inhalation and at 6 and 24 hours post challenge. Spirometry, pulse, blood pressure and temperature were recorded prior to challenge and at hourly intervals until 8 hours and at 24 hours post challenge. There was no change in cardiovascular parameters, temperature or spirometry with either exposure in either group. In normal subjects inhalation of LPS caused a significant rise in percentage neutrophils at both 6 hours and 24 hours (baseline 58.5±2.8; 6 hours 84.1±2.3, p<0.001; 24 hours 72.6±2.6, p=0.02). However, a similar effect was seen following inhalation of placebo (baseline 52.9±4.8; 6 hours 80.1±5.7, p=0.01; 24 hours 61.2±7.8, p=0.16). There was no significant difference between placebo and active treatments at any time. In the asthmatic patients there was a rise in percentage neutrophils after LPS which was maximal at 6 hours and remained elevated at 24 hours (baseline 32.9±8.1; 6 hours 85.5±3.3, p<0.05; 24 hours 55.2±7.1, p<0.05). The percentage neutrophil count in the LPS group was significantly higher than in the placebo group (p=0.001). There was a non-significant rise in percentage neutrophils following placebo exposure. We conclude that inhalation of LPS causes a neutrophilic inflammation in asthmatic subjects, over and above that caused by placebo inhalation.
Emms JC, Rogers DF, 1997, Cigarette smoke-inhibition of neurogenic bronchoconstriction in guinea-pigs in vivo: involvement of exogenous and endogenous nitric oxide, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 122, Pages: 779-785, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 3
Rogers DF, 1997, In vivo preclinical test models for studying airway mucus secretion, PULMONARY PHARMACOLOGY & THERAPEUTICS, Vol: 10, Pages: 121-128, ISSN: 1094-5539
- Author Web Link
- Cite
- Citations: 6
Rogers DF, 1997, Neurogenic inflammation in lung disease: burnt out?, Inflammopharmacology, Vol: 5, Pages: 319-329, ISSN: 0925-4692
Neurogenic inflammation results from activation of sensory nerves which, acting in an 'efferent' manner, release sensory neuropeptides to induce a wide variety of physiological and immunological responses. This process is easy to demonstrate experimentally in the airways of small laboratory animal species but in human airways is equivocal and, at best, minor compared with cholinergic neural control. Nevertheless, sensory neuropeptides (calcitonin gene-related peptide and the tachykinins, substance P and neurokinin A) induce airway responses in both laboratory animals and humans which suggest a potential for sensory-efferent control of human airways. In addition, there is indirect evidence for an increased 'expression' of sensory nerves and tachykinin receptors in asthma and bronchitis, which indicates that neurogenic inflammation contributes to pathophysiology of these airway conditions. In contrast, clinical trials using different classes of drugs to inhibit sensory nerve responses have failed to resolve whether neurogenic inflammation is involved in asthma, although there are concerns about the relevance of some of these studies. In contrast to their involvement in airway neurogenic inflammation, sensory nerves may be important in initiating protective reflexes, including coughing and sneezing, acting via their afferent pathways. Thus, although flickering, the concept of neurogenic inflammation in lung disease is not yet burnt out. However, it needs the rekindling of interest which re-evaluation as a protective process may bring, together with data from more appropriate clinical studies in asthma and chronic bronchitis.
Newman TM, Robichaud A, Rogers DF, 1996, Microanatomy of secretory granule release from guinea pig tracheal goblet cells, AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, Vol: 15, Pages: 529-539, ISSN: 1044-1549
- Author Web Link
- Cite
- Citations: 25
Ramnarine SI, Haddad EB, Khawaja AM, et al., 1996, On muscarinic control of neurogenic mucus secretion in ferret trachea, JOURNAL OF PHYSIOLOGY-LONDON, Vol: 494, Pages: 577-586, ISSN: 0022-3751
- Author Web Link
- Cite
- Citations: 58
Khawaja AM, Rogers DF, 1996, Tachykinins: Receptor to effector, INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, Vol: 28, Pages: 721-738, ISSN: 1357-2725
- Author Web Link
- Cite
- Citations: 211
Ramnarine SI, Khawaja AM, Barnes PJ, et al., 1996, Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea in vitro, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 118, Pages: 998-1002, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 22
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.